Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Vital KSK Holdings, Inc. ( (JP:3151) ).
Vital KSK Holdings, Inc. has announced the establishment of a new subsidiary, MedLeap Pharma Company Limited, which will focus on pharmaceutical research and development. The subsidiary is fully owned by Vital KSK Holdings and will be led by Yuichi Kobayashi, an executive officer of the parent company. The impact of this new subsidiary on the company’s financial results for the fiscal year ending March 2026 is expected to be minimal.
The most recent analyst rating on (JP:3151) stock is a Buy with a Yen1385.00 price target. To see the full list of analyst forecasts on Vital KSK Holdings, Inc. stock, see the JP:3151 Stock Forecast page.
More about Vital KSK Holdings, Inc.
Vital KSK Holdings, Inc. operates in the pharmaceutical industry, focusing on the research, development, manufacturing, and sales of pharmaceuticals. The company is based in Tokyo and is listed on the TSE Prime Market.
Average Trading Volume: 129,191
Technical Sentiment Signal: Strong Buy
Current Market Cap: Yen59.66B
For an in-depth examination of 3151 stock, go to TipRanks’ Overview page.